Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass

The Journal of Thoracic and Cardiovascular Surgery
A H FinnN Moat

Abstract

The inflammatory response to cardiopulmonary bypass includes activation of complement and induction of several neutrophil activation pathways. A recombinant soluble form of complement receptor 1 was used as a specific inhibitor of complement activation in simulated cardiopulmonary bypass circuits. Substantial complement activation was observed in these circuits with progressive accumulation of both plasma C3a and terminal complement complex. Soluble complement receptor 1 resulted in a significant reduction in C3a levels (p < 0.01) but did not inhibit terminal complement complex generation. A marked rise in neutrophil CD11b/CD18 expression, simultaneous loss of L-selectin expression, and a progressive accumulation of plasma elastase-alpha 1-antitrypsin occurred and were not affected by soluble complement receptor. However, generation of interleukin-8 in the circuits was inhibited (p < 0.05) by pretreatment with soluble complement receptor. These data suggest that changes in neutrophil activation seen during cardiopulmonary bypass may not be induced directly by anaphylatoxin generation.

References

Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·D T Fearon
Oct 1, 1992·The Annals of Thoracic Surgery·V VidemJ L Svennevig
Feb 14, 1991·Nature·N P Gerard, C Gerard
Jan 1, 1991·Annual Review of Immunology·J J OppenheimK Matsushima
Aug 2, 1990·Nature·T A Springer
Oct 1, 1990·The Annals of Thoracic Surgery·S D TennenbergJ S Solomkin
Jan 1, 1990·Scandinavian Journal of Thoracic and Cardiovascular Surgery·L NilssonS O Nyström
Jan 1, 1990·The Annals of Thoracic Surgery·R W Colman
Dec 1, 1983·The Journal of Thoracic and Cardiovascular Surgery·J K KirklinA D Pacifico
Jan 1, 1993·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·N E MoatT W Evans
Mar 1, 1993·The Annals of Thoracic Surgery·A M GillinovA Herskowitz

❮ Previous
Next ❯

Citations

Sep 2, 2000·The Annals of Thoracic Surgery·A J ParryF L Hanley
May 16, 1998·The Annals of Thoracic Surgery·H L LazarR J Shemin
Feb 4, 1999·The Annals of Thoracic Surgery·G Asimakopoulos, K M Taylor
May 13, 1999·The Annals of Thoracic Surgery·A L PiconeG Nieman
Jun 20, 1998·British Journal of Haematology·S Bannan, P G Martin
Jan 28, 2005·Journal of Cardiac Surgery·John C ChenUNKNOWN Pexelizumab Study Investigators
Aug 15, 1998·Vox Sanguinis·T E Mollnes
Aug 1, 1997·Archives of Disease in Childhood·I M Balfour-LynnR Dinwiddie
Oct 3, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·S K Shernan, C D Collard
Feb 16, 2000·The Tohoku Journal of Experimental Medicine·T TanitaS Fujimura
Aug 13, 2015·Research in Veterinary Science·Takeshi MizunoMasami Uechi
Jan 23, 2003·The Journal of Thoracic and Cardiovascular Surgery·Yukio SatoYuzuru Sakakibara
Aug 4, 2005·The Journal of Thoracic and Cardiovascular Surgery·Yukio SatoYasunori Sohara
Sep 16, 2014·SpringerPlus·Davinia E WithingtonLarry C Lands
Apr 10, 2009·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Shinya UgakiShunji Sano
Aug 24, 1999·Perfusion·M J Elliott
Oct 5, 2018·Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs·Yukinobu GotoYukio Sato
Jan 16, 1999·Journal of the American Society of Nephrology : JASN·A R RosenkranzG J Zlabinger
Dec 2, 1998·The Journal of Thoracic and Cardiovascular Surgery·M TofukujiF W Sellke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.